Abcellera Stock Today

ABCL
 Stock
  

USD 13.68  0.32  2.40%   

Market Performance
17 of 100
Odds Of Distress
Less than 17
Abcellera Biologics is selling for 13.68 as of the 14th of August 2022. This is a 2.40 percent up since the beginning of the trading day. The stock's lowest day price was 13.14. Abcellera Biologics has less than a 17 % chance of experiencing some financial distress in the next two years of operation and had a solid performance during the last 90 days. Equity ratings for Abcellera Biologics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 15th of June 2022 and ending today, the 14th of August 2022. Click here to learn more.
Fiscal Year End
December
IPO Date
11th of December 2020
Category
Healthcare
ISIN
CA00288U1066
AbCellera Biologics Inc. develops antibody discovery platform. The company was incorporated in 2012 and is headquartered in Vancouver, Canada. Abcellera Biologics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 281.58 M outstanding shares of which 19.23 M shares are presently shorted by private and institutional investors with about 5.07 trading days to cover. More on Abcellera Biologics

Moving together with Abcellera Biologics

0.8AIKIAIkido Pharma Earnings Call  TomorrowPairCorr

Moving against Abcellera Biologics

0.74ALRNAileron Therapeutics Earnings Call  TomorrowPairCorr
0.68AYLAAyala Pharmaceuticals Earnings Call  TomorrowPairCorr
0.66ABCAmerisourcebergen Corp Fiscal Year End 3rd of November 2022 PairCorr
0.57AGTCApplied Genetic Tech Fiscal Year End 22nd of September 2022 PairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Abcellera Biologics Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Abcellera Biologics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Abcellera Biologics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Abcellera Biologics appears to be risky and price may revert if volatility continues
About 29.0% of the company shares are held by company insiders
Latest headline from seekingalpha.com: AbCellera stock rises 17 percent as continued strength from COVID royalties overshadows Q2 miss - Seeking Alpha
New SymbolABCL1
Fama & French Classification
Average Analyst Recommendation
Analysts covering Abcellera Biologics report their recommendations after researching Abcellera Biologics' financial statements, talking to executives and customers, or listening in on Abcellera Biologics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Abcellera Biologics. The Abcellera consensus assessment is calculated by taking the average forecast from all of the analysts covering Abcellera Biologics.
Strong Buy5 Opinions
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Abcellera Biologics based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Abcellera Biologics financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
HealthyDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares251.6 M275.8 M
Significantly Down
Increasing
Slightly volatile
Weighted Average Shares Diluted298.4 M318.3 M
Notably Down
Increasing
Slightly volatile
Net Cash Flow from Operations263.9 M244.6 M
Significantly Up
Increasing
Slightly volatile
Total Assets1.4 B1.3 B
Significantly Up
Increasing
Slightly volatile
Total Liabilities316 M292.8 M
Significantly Up
Increasing
Slightly volatile
Current Assets745.7 M929.8 M
Significantly Down
Increasing
Slightly volatile
Current Liabilities98 M120.7 M
Significantly Down
Increasing
Slightly volatile
Total Debt39.3 M36.4 M
Significantly Up
Increasing
Slightly volatile
Return on Average Assets0.120.129
Significantly Down
Increasing
Slightly volatile
Gross Margin0.890.9
Fairly Down
Decreasing
Slightly volatile
Asset Turnover0.340.315
Significantly Up
Decreasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Abcellera Biologics' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Financial Strength
Abcellera Biologics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Abcellera Biologics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Abcellera Biologics' financial leverage. It provides some insight into what part of Abcellera Biologics' total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Abcellera Biologics' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Abcellera Biologics deploys its capital and how much of that capital is borrowed.
Liquidity
Abcellera Biologics cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 40.28 M in liabilities with Debt to Equity (D/E) ratio of 0.03, which may suggest the company is not taking enough advantage from borrowing. Abcellera Biologics has a current ratio of 5.39, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Abcellera Biologics until it has trouble settling it off, either with new capital or with free cash flow. So, Abcellera Biologics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Abcellera Biologics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Abcellera to invest in growth at high rates of return. When we think about Abcellera Biologics' use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

263.89 Million
Abcellera Biologics (ABCL) is traded on NASDAQ Exchange in USA. It is located in 2215 Yukon Street and employs 400 people. Abcellera Biologics is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with current market capitalization of 3.13 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Abcellera Biologics's market, we take the total number of its shares issued and multiply it by Abcellera Biologics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Abcellera Biologics conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 281.58 M outstanding shares of which 19.23 M shares are presently shorted by private and institutional investors with about 5.07 trading days to cover. Abcellera Biologics currently holds about 786.05 M in cash with 235.26 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.76.
Check Abcellera Biologics Probability Of Bankruptcy
Ownership
Abcellera Biologics retains a total of 281.58 Million outstanding shares. Abcellera Biologics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.

Ownership Allocation (%)

Check Abcellera Ownership Details

Abcellera Stock Price Odds Analysis

What are Abcellera Biologics' target price odds to finish over the current price? Based on a normal probability distribution, the odds of Abcellera Biologics jumping above the current price in 90 days from now is near 1%. The Abcellera Biologics probability density function shows the probability of Abcellera Biologics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Abcellera Biologics has a beta of 0.5786. This suggests as returns on the market go up, Abcellera Biologics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Abcellera Biologics will be expected to be much smaller as well. Moreover, the company has an alpha of 1.171, implying that it can generate a 1.17 percent excess return over DOW after adjusting for the inherited market risk (beta).
  Odds Below 13.68HorizonTargetOdds Above 13.68
99.05%90 days
 13.68 
0.95%
Based on a normal probability distribution, the odds of Abcellera Biologics to move above the current price in 90 days from now is near 1 (This Abcellera Biologics probability density function shows the probability of Abcellera Stock to fall within a particular range of prices over 90 days) .

Abcellera Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Abcellera Biologics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Abcellera Biologics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Abcellera Biologics' value.
InstituionSecurity TypeTotal SharesValue
Baillie Gifford CoCommon Shares13.4 M142.2 M
Blackrock IncCommon Shares11.8 M125.9 M
Group One Trading LpCall Options266 K2.8 M
View Abcellera Biologics Diagnostics

Abcellera Biologics Historical Income Statement

Abcellera Biologics Income Statement is one of the three primary financial statements used for reporting Abcellera's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Abcellera Biologics revenue and expense. Abcellera Biologics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Abcellera Biologics Net Income Common Stock is relatively stable at the moment as compared to the past year. The company's current value of Net Income Common Stock is estimated at 165.58 Million. Operating Expenses is expected to hike to about 184.3 M this year, although the value of Weighted Average Shares will most likely fall to nearly 251.6 M. View More Fundamentals

Abcellera Stock Against Markets

Picking the right benchmark for Abcellera Biologics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Abcellera Biologics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Abcellera Biologics is critical whether you are bullish or bearish towards Abcellera Biologics at a given time.

Similar Equity Warning - ABCL

Abcellera Biologics was forked

The entity Abcellera Biologics with a symbol ABCL was recently forked. You can potentially use ALLIANCE BANCORP with a symbol ABCL1 from now on.

Invested in Abcellera Biologics?

You need to understand the risk of investing before taking a position in Abcellera Biologics. The danger of trading Abcellera Biologics is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Abcellera Biologics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Abcellera Biologics. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Abcellera Biologics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please continue to Trending Equities. Note that the Abcellera Biologics information on this page should be used as a complementary analysis to other Abcellera Biologics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Complementary Tools for Abcellera Stock analysis

When running Abcellera Biologics price analysis, check to measure Abcellera Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abcellera Biologics is operating at the current time. Most of Abcellera Biologics' value examination focuses on studying past and present price action to predict the probability of Abcellera Biologics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Abcellera Biologics' price. Additionally, you may evaluate how the addition of Abcellera Biologics to your portfolios can decrease your overall portfolio volatility.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Is Abcellera Biologics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abcellera Biologics. If investors know Abcellera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abcellera Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
0.46
Market Capitalization
3.8 B
Quarterly Revenue Growth YOY
0.66
Return On Assets
0.12
Return On Equity
0.18
The market value of Abcellera Biologics is measured differently than its book value, which is the value of Abcellera that is recorded on the company's balance sheet. Investors also form their own opinion of Abcellera Biologics' value that differs from its market value or its book value, called intrinsic value, which is Abcellera Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abcellera Biologics' market value can be influenced by many factors that don't directly affect Abcellera Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abcellera Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine Abcellera Biologics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abcellera Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.